Pfizer Inc (PFE)

PFE (NYSE:Drugs) EQUITY
$35.00
pos +0.00
+0.00%
Today's Range: 0.00 - 0.00 | PFE Avg Daily Volume: 29,757,000
Last Update: 03/30/15 - 4:00 PM EDT
Volume: 0
YTD Performance: 12.36%
Open: $0.00
Previous Close: $35.00
52 Week Range: $27.51 - $35.45
Oustanding Shares: 6,128,855,392
Market Cap: 212,025,718,448
6-Month Chart
TheStreet Ratings Grade for PFE
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 8 8 7 7
Moderate Buy 1 1 1 1
Hold 4 4 3 4
Moderate Sell 0 0 0 0
Strong Sell 1 1 1 1
Mean Rec. 1.93 1.93 1.92 2.00
Latest Dividend: 0.28
Latest Dividend Yield: 3.24%
Dividend Ex-Date: 02/04/15
Price Earnings Ratio: 24.49
Price Earnings Comparisons:
PFE Sector Avg. S&P 500
24.49 24.30 27.35
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
11.54% 9.79% 54.56%
GROWTH 12 Mo 3 Yr CAGR
Revenue -3.80 -0.26 -0.10
Net Income -58.50 0.04 0.01
EPS -55.50 0.13 0.04
Earnings for PFE:
EBITDA 19.04B
Revenue 49.61B
Average Earnings Estimates
Qtr (03/15) Qtr (06/15) FY (12/15) FY (12/16)
Average Estimate $0.50 $0.54 $2.08 $2.24
Number of Analysts 7 7 10 9
High Estimate $0.56 $0.55 $2.10 $2.35
Low Estimate $0.45 $0.53 $2.06 $2.13
Prior Year $0.57 $0.58 $2.26 $2.08
Growth Rate (Year over Year) -12.78% -7.14% -8.10% 7.79%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
By

Jim Cramer

 | Mar 27, 2015 | 12:00 PM EDT

You can't help but feel better about both groups.

By

Robert Lang

 | Mar 25, 2015 | 7:23 AM EDT

And the chart says it's in for a very solid 2015.

bullishPfizer estimates, target boosted at Jefferies

Mar 23, 2015 | 7:48 AM EDT

Shares of PFE now seen reaching $45, according to Jefferies. Estimates also upped, as the Ibrance should drive growth and the company could continue to make accretive acquisitions. Buy rating.  

By

David Peltier

 | Mar 20, 2015 | 10:00 AM EDT

Which dividend stocks gain or suffer from the next currency move?

 

By

Jim Cramer

 | Feb 23, 2015 | 11:59 AM EST

It is no pipedream that the stock could trade to $240.

By

Gary Morrow

 | Feb 18, 2015 | 3:13 PM EST

A continued fade back down offers a buying opportunity.

bullishPfizer upgraded at BMO

Feb 9, 2015 | 7:10 AM EST

PFE was upgraded from Market Perform, to Outperform, BMO Capital said. $36 price target. Hospira deal could mark an inflection point in valuation. 

By

Jim Cramer

 | Feb 6, 2015 | 7:40 AM EST

The logic of owning the pure play is attractive.

bullishPfizer estimates, target increased at BMO

Feb 4, 2015 | 8:08 AM EST

PFE estimates were raised through 2016, BMO Capital said. Company received accelerated approval for breast cancer treatment. Market Perform rating and new $33 price target. 

By

Bret Jensen

 | Jan 31, 2015 | 12:00 PM EST

The financial version will affect global equity markets.

Early yesterday I spoke here about the position we had on RH, and late in the day we sold ...
Exxon Mobil (XOM) shares are back up near the $85.75 level. This area was solid support fo...
Good closing piece by "El Capitan" on the nature of buyers these days. I totally agree. As...

REAL MONEY PRO'S BEST IDEAS

Columnist Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.